Our proof of concept studies showed that combined delivery of HNP surface functionalised with cytochrome C (HNP-c) and paclitaxel (PTX), resulted in the most notable effects across hepatocellular carcinoma cell line (HepG2), hepatocellular carcinoma cell line (Huh-7D12), and human endothelial liver cancer (SK-hep-1) cell lines [14]. Here, CYCS is linked to hepatocellular carcinoma.